Boehringer Ingelheim

This study is testing a new drug called BI 764532 for adults with an aggressive type of brain cancer (glioma) that has stopped responding to standard treatments. The drug works by linking the patient's own immune cells to the cancer cells to help the body fight the tumor. The mai…

This early-stage study is testing a new combination of two immunotherapy drugs, obrixtamig and ezabenlimab, for adults with advanced small cell lung cancer or similar neuroendocrine tumors that have stopped responding to standard treatments. The main goal is to find the highest d…

This study is monitoring the long-term safety of Ofev capsules in Japanese patients with lung disease caused by systemic scleroderma. Researchers are tracking side effects, particularly stomach and intestinal issues like diarrhea and nausea, in real-world use. The goal is to conf…

This study is testing the long-term safety and effectiveness of the drug spesolimab for people with generalized pustular psoriasis (GPP), a serious skin condition. Participants who previously took spesolimab in earlier trials receive the drug for nearly five years to see how well…

This is an early safety study for adults with advanced solid tumors (like lung or colorectal cancer) that have a specific KRAS G12C mutation and have stopped responding to standard treatments. Researchers are testing a new oral drug, BI 1823911, for the first time in people, both…

This early-stage trial is testing a new oral drug called zongertinib for people with advanced solid tumors, mainly non-small cell lung cancer, that have specific changes in the HER2 gene. The first part aims to find the highest safe dose. The second part will see if the drug can …

This study follows 5 people with cystic fibrosis for 15 years to monitor the long-term safety and lasting effects of a single-dose inhaled gene therapy they received in a previous trial. Participants do not receive new treatment but undergo regular health checks and lung function…

This is an early-stage study to find a safe dose of a new immunotherapy drug, BI 770371, given alone or with another immunotherapy called ezabenlimab. It is for adults with advanced solid tumors who have no other effective treatment options left. The main goal is to see how much …

This study is testing a medication called spesolimab for adults who experience repeated, severe flare-ups of generalized pustular psoriasis (GPP), a serious skin condition. Participants receive spesolimab as an intravenous infusion at the start of a flare and may receive a second…

This study is monitoring the long-term safety and effectiveness of Jardiance tablets in over 1,000 real-world patients with chronic kidney disease in Japan. It aims to see how well the drug works and what side effects occur when used daily over a long period. The study is not tes…

This study is testing the long-term safety and effectiveness of an oral medication called BI 1291583 for adults with bronchiectasis, a condition that causes lung damage and frequent infections. It is open only to people who completed a previous related study. Participants take on…

This large, late-stage study is checking if a new weekly injectable weight-loss medicine called survodutide is safe for the heart. It involves over 5,500 adults who are overweight or have obesity and also have heart disease, kidney disease, or other weight-related health risks. P…

This study aims to understand the long-term safety of an experimental cancer pill called brigimadlin. It includes 90 adults with various solid tumors who have already been taking the drug in a previous trial. Participants continue taking the pills every three weeks while doctors …

This study is testing a combination of four different drugs for adults with advanced head and neck cancer that has returned or spread after prior treatment. The goal is to see if this multi-pronged approach can shrink tumors. The drugs work together by helping the immune system f…

This early-stage study aims to find a safe dose of an experimental drug called BI 764532 when given with standard chemotherapy. It is for adults whose extensive-stage small cell lung cancer has worsened after initial platinum-based treatment. The drug is designed to help the body…

This early-stage study is testing a new combination treatment for pancreatic cancer. It combines a cancer vaccine designed to train the immune system to attack cancer cells with an immunotherapy drug called ezabenlimab. The study aims to find safe doses and see if this approach c…

This is an early-stage study to check the safety and how the body processes a new oral medicine called BI 3000202. It involves about 16 adults with specific rare genetic conditions where the immune system is overactive. Participants will take the medicine for about 9 months while…

This study is checking if the heart benefits seen for the diabetes drug empagliflozin in controlled trials also happen for regular patients in real-world doctor's offices and hospitals. It will follow about 230,000 adults with type 2 diabetes who are starting this drug or a simil…

This is the first study in humans testing a new drug, BI 1701963, designed to block a specific cancer-driving mutation called KRAS. It is being tested alone and combined with an existing drug, trametinib, in 71 adults with advanced solid tumors where previous treatments have fail…

This study is testing whether a weekly injectable medicine called survodutide helps adults with type 2 diabetes and overweight or obesity lose weight. About 755 participants will be randomly assigned to receive one of two doses of the drug or a placebo (a dummy injection) for 76 …

This large study in Japan is investigating whether SGLT2 inhibitor drugs, often used for diabetes, can help delay or reduce anemia in people with chronic kidney disease (CKD). Researchers will compare 15,000 patients who take these drugs with those who do not, tracking when anemi…

This study is testing a medicine called BI 1584862 to see if it can slow the progression of geographic atrophy, a severe form of dry age-related macular degeneration that causes permanent vision loss. About 150 adults aged 50+ with this condition will be randomly assigned to rece…

This early-stage study is testing a new drug called BI 764532 (obrixtamig) when combined with standard chemotherapy and immunotherapy for extensive-stage small cell lung cancer. The main goal is to find the highest dose patients can safely tolerate. Researchers will also check if…

This is a first-in-human study to find a safe dose of a new immunotherapy drug called BI 765179 for adults with advanced solid tumors. In the first part, researchers will test the drug alone and combined with another immunotherapy (ezabenlimab). In the second part, they will test…

This study is testing a new investigational eye injection called BI 771716 against an already approved treatment, pegcetacoplan, for people with geographic atrophy. Geographic atrophy is an advanced form of age-related macular degeneration that causes progressive, permanent visio…

This study is following 2000 patients for up to 10 years to see how well the approved drug nintedanib works long-term for people with lung scarring caused by scleroderma. Researchers will track how the disease progresses, measure survival rates, and check if the drug improves pat…

This study is testing a new drug called BI 3032950 for adults with moderate to severe ulcerative colitis who haven't gotten better with other treatments. Participants first receive the drug through an IV every 4 weeks for 12 weeks, then switch to under-the-skin injections for up …

This study is testing a smartphone app called CT-155, designed to help adults with schizophrenia manage their 'negative symptoms,' like lack of motivation and reduced pleasure. Participants use the app for 16 weeks alongside their regular treatment, and researchers measure change…

This study analyzes existing medical records to understand how patients with HER2-altered metastatic breast cancer are treated in real-world settings. Researchers are examining treatment patterns and survival outcomes for nearly 8,000 patients across multiple lines of therapy. Th…

This early-stage study aims to understand how a common antifungal medication (itraconazole) affects blood levels of an experimental drug called BI 764198. Researchers will give both medicines to 14 healthy male volunteers to measure their interaction. The results will help determ…

This study aims to understand how two new experimental drugs travel to and gather in tumors in people with advanced head and neck cancer, lung cancer, or melanoma. Participants receive one of the new drugs along with an existing immunotherapy, and doctors use special PET scans to…

This study is observing patients in Spain who have pulmonary fibrosis and are taking the medication nintedanib. The goal is to see how satisfied they are with a special support program and to monitor their quality of life, symptoms, and medication use over one year. It is not tes…

This study aims to understand how SGLT2i diabetes drugs are prescribed and used in France by analyzing health records. It will track over 500,000 patients starting this treatment to see if it is linked to real-world health outcomes like heart attacks, strokes, heart failure, and …

This early-stage study aims to understand how a new drug, BI 3000202, is processed by the body. It involves healthy volunteers and will measure how the drug is absorbed, distributed, and eliminated. The goal is to gather basic information about the drug's behavior to help plan fu…

This early-stage study aims to understand if taking a new investigational drug, BI 764198, changes how the body absorbs and processes metformin, a common medication for type 2 diabetes. It involves 14 healthy adult participants who will take both drugs together and metformin alon…

This study aims to understand how long patients with lung scarring diseases like Idiopathic Pulmonary Fibrosis (IPF) continue taking their antifibrotic medications in real-world French healthcare settings. It will follow over 10,000 patients who started treatment between 2018 and…

This study aims to compare how two different versions of the experimental obesity drug survodutide are absorbed by the body. About 100 healthy adults with a higher body weight will inject one of the two drug formulations weekly for about six and a half months. Researchers will me…

This study aims to learn how tracking cancer DNA in the blood relates to treatment response. It will observe 102 adults with lung, colorectal, or pancreatic cancer who are receiving standard care. Researchers will collect blood samples over time to see if changes in cancer DNA le…